



(51) International Patent Classification:

A61K 9/68 (2006.01) *A61K 31/05* (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:

PCT/AU2012/001253

(22) International Filing Date:

17 October 2012 (17.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2011904326 19 October 2011 (19.10.2011) AU

(71) Applicant: **NAD LIFE PTY LTD** [AU/AU]; 13/2-10
Central Avenue, Thornleigh, New South Wales 2120 (AU).(72) Inventors: **GRANT, Ross Stewart**; 31 Rosebery Road,
Kellyville, New South Wales 2155 (AU). **LINDBECK,
Keith**; 17 Babers Road, Cooranbong, New South Wales
2265 (AU).(74) Agent: **HODGKINSON McINNES PATENTS**; Level
21, 201 Elizabeth Street, Sydney, New South Wales 2000
(AU).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITIONS OF RESVERATROL

**FIGURE 3c**

(57) **Abstract:** A pharmaceutical composition for administering a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof to a subject. The absorption of resveratrol occurs through the subject's buccal/sublingual membranes, thereby by-passing first pass metabolism by the liver.